<DOC>
	<DOC>NCT00904800</DOC>
	<brief_summary>This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.</brief_summary>
	<brief_title>AZD0837 Extended Release (ER) Japan Study</brief_title>
	<detailed_description />
	<criteria>Healthy male Japanese subject aged between 20 to 45 years inclusive Acute illness (including ongoing or history of liver disease), trauma or surgical procedures within two weeks before Visit 1 or pre first dose in Visit 2 Intake of another investigational drug within 4 months before Visit 1 or pre first dose in Visit 2 Blood donation and/or sampling in excess of 200 mL of whole blood within the preceding 4 weeks, 400 mL of whole blood within the preceding 12 weeks and/or 1200 mL of whole blood within the preceding 12 months, before Visit 1 or pre first dose in Visit 2</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Healthy volunteers</keyword>
</DOC>